
Novo Nordisk raised its adjusted growth outlook after third-quarter sales and operating profit exceeded estimates, led by continued demand for its obesity treatments.
Novo Nordisk raised its 2026 outlook after third-quarter sales and adjusted operating profit beat expectations, with Wegovy pill sales reaching DKK 5,394 million. The company now expects adjusted sales and operating profit growth of -2% to +2% at constant exchange rates.
The new range compares with its previous forecast of -6% to flat growth for both measures. Novo said the improved outlook reflects higher expectations for GLP-1 product sales.
Third-quarter sales rose 4% at constant exchange rates to DKK 79.2 billion, above FactSet’s DKK 73.6 billion estimate. Adjusted operating profit increased 27% at constant exchange rates to DKK 31,720 million, compared with an analyst estimate of DKK 28.6 billion, according to CNBC.
Reported operating profit moved in the opposite direction, falling 9% at constant exchange rates. Novo attributed the decline to DKK 8.7 billion in non-cash impairment charges related to ziltivekimab and changes to its manufacturing network.
The Wegovy pill had launched in the US, UAE, UK and Germany by quarter-end. Novo said subsequent launches in four more countries brought the total number of markets to eight.
This article was produced with the help of AI technology. Based on reporting by the outlets listed above.